Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 92

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 92
---
., a subsidiary of OC Oerlikon
AG, a global provider of industrial technology based in Switzerland, with a focus on manufacturing of specialty materials, primarily
nickel-based metal powders. In his most recent role at Oerlikon as the General Manager, Composite Materials for Aerospace, Electronics,
Mining and Energy, he successfully led a team of 70 - 80 employees through the global pandemic and into back-to-back record years for
revenue and profitability. Additionally, he served as the VP of Operations, Advanced Materials R& D for Infection Prevention and Control
at Exciton Technologies, Inc., where he led the completion of product development and pilot manufacturing operations for the company’s
commercialization of their proprietary antimicrobial silver technology. Other career appointments include Director, Product Development
and Director, Engineering at Nucryst Pharmaceuticals Corp.

Michael Teifelis a leading industry executive
with a career spanning over 20 years in various therapeutic areas, including endocrinology and oncology. He has deep experience in translating
research into clinical development. Over the course of his career, he has gained particular expertise in the design and implementation
of non-clinical development programs for small molecule drugs, peptides, targeted therapies, and biologics, as well as in the continued
non-clinical evaluation of drug candidates for global registration. Dr Teifel joined Aeterna Zentaris having held various positions in
industry with increasing responsibilities in pharmacology, pharmacokinetics, toxicology and translational sciences. He began his career
in industry at Roche Diagnostics in the area of delivery systems / non-viral gene therapy. In 1999, Dr. Teifel joined the biotech start-up,
Munich Biotech in Martinsried, Germany as a co-founder. As head of pharmacology & toxicology, he was responsible for the evaluation
and non-clinical development of a novel vascular targeting technology for the development of anti-tumor diagnostics and therapeutics.
In 2004, Dr. Teifel started his first term at Aeterna Zentaris where he held several positions in the field of preclinical development
and translational research. In his capacity he was, among others, responsible for preparation of the non-clinical dossier for registration
of macimorelin in the U. S. and EU in the indication AGHD. In 2019, Dr. Teifel left Aeterna Zentaris to pursue his career in non-clin